RIKEN TECHNOS CORPORATION
4220・Prime Market・Chemicals
Business
Riken Technos Corporation is a specialty synthetic resin processing manufacturer founded in 1951, comprising the company and 16 consolidated subsidiaries. It manufactures and sells PVC Compound, Elastomer Compound, Functional Film, and Food Packaging Materials for four market segments: Transportation (automobiles, railways, ships), Daily Life & Healthcare (medical and daily living materials, food packaging materials), Electronics (energy, telecommunications, IT devices), and Building & Construction (housing, architecture, civil engineering). In addition to domestic manufacturing sites (Saitama, Mie, Gunma, etc.), the company operates globally with overseas bases in Thailand, Indonesia, Vietnam, the United States, China, South Korea, and India.
Business Model
A manufacturing-and-sales business model in which the company and its overseas subsidiaries manufacture PVC Compound, Elastomer Compound, Functional Film, and Food Packaging Materials, and sell them directly to customers across four market segments. The company continuously promotes the pass-through of raw material costs into selling prices (price optimization) to maintain and improve profit margins, while securing local-production-for-local-consumption cost competitiveness through local manufacturing and sales at overseas bases centered on ASEAN. R&D expenses on a consolidated basis amounted to ¥1,977 million (FY2026 (ending March 2026)), aimed at differentiation through the development of high-value-added products.
Company Strengths
The company operates consolidated subsidiaries in Thailand, Indonesia, Vietnam, the United States, China, South Korea, and India, building a local manufacturing and sales structure. In FY2026 (ending March 2026), expanded Compound sales in ASEAN contributed to revenue growth in the TR, DH, and EL segments, with global order intake reaching ¥134,734,843 thousand, up 104.5% year on year.
By supplying products to four market segments—automotive, medical, wire/cable, and building materials—with differing economic cycles, the company diversifies the risk of dependence on any single market. In FY2026 (ending March 2026), TR, EL, and BC posted revenue growth while DH saw a slight revenue decline, but consolidated net sales remained on a stable growth trajectory at ¥131,377 million.
Amid rising raw material costs, segment profit increased 87.7% year on year in the EL segment and 11.9% in the DH segment, demonstrating the company's ability to pass on costs through price optimization across multiple segments. Consolidated operating profit expanded roughly 1.8-fold over four years, from ¥6,292 million in FY2022 (ended March 2022) to ¥11,408 million in FY2026 (ending March 2026).
ENVALITH's Perspective
Performance Trend
In FY2026 (ending March 2026), revenue was ¥131,377 million (up 2.5% year-on-year), operating profit was ¥11,408 million (up 8.8%), ordinary profit was ¥11,786 million (up 11.3%), and profit attributable to owners of the parent was ¥7,569 million (up 2.7%), achieving increases across all profit line items. The operating profit margin improved to 8.7% (from 8.2% in the previous period). As external factors, the impact of U.S. trade policy and demand slowdown due to stagnation in the Chinese real estate market affected some segments, but expanded sales of medical products and compounds in ASEAN, along with price optimization both domestically and internationally, supported business performance. For FY2027 (ending March 2027), revenue is projected at ¥142,000 million and operating profit at ¥12,000 million, but net profit is expected to decline to ¥6,800 million (down 10.2%).
Growth Strategy
Pursuing growth under "One Vision, New Stage 2027" with three pillars: Global One Company, new product development, and sustainability
Domestic and overseas market-based business units are collaborating to promote expanded sales of PVC Compound and Elastomer Compound to non-Japanese automotive, medical, and wire manufacturers, primarily in ASEAN. In FY2026 (ending March 2026), this contributed to revenue growth in the TR and DH segments in ASEAN, with sales to Thailand expanding to ¥16,970 million.
Continuously implementing the pass-through of elevated raw material costs to selling prices. In FY2026 (ending March 2026), price optimization became evident in the EL and BC segments, with EL segment profit sharply recovering to ¥1,835 million, up 87.7% year on year. The operating margin improved by 0.5 percentage points year on year to 8.7%.
As the third pillar of the medium-term management plan, the company is promoting the development and expanded sales of unique functional films in the optical field and high-value-added PVC Compound for the medical market. In the DH segment, expanded sales to the ASEAN medical market contributed to increased profit, with segment profit reaching ¥3,941 million, up 11.9% year on year.
Working on environmental initiatives, including decarbonization, and on enhancing governance and risk management. In FY2026 (ending March 2026), the company recorded a provision for business restructuring losses of ¥450 million and began optimizing its business portfolio. In the second year of the medium-term management plan, "sustainability" continues to be positioned as a core pillar of management alongside "earning power."
Last updated: July 19, 2026